Aethlon Medical, Inc. (AEMD)
| Previous close | 1.5250 |
| Open | 1.5000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 1.3300 - 1.5000 |
| 52-week range | 1.3300 - 5.0000 |
| Volume | |
| Avg. volume | 7,916 |
| Market cap | 3.604M |
| Beta (5Y monthly) | 1.94 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.0100 |
| Earnings date | 26 Jun 2024 - 01 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 25.00 |
PR NewswireAethlon Medical Enters Into Materials Transfer Agreement for Santersus AG's NucleoCapture and HemoNucleoCapture Devices
Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it entered into a Materials Transfer Agreement (MTA) with Santersus AG, a Zurich-London based, privately held therapeutic medical device company, for Santersus' NucleoCapture and HemoNucleoCapture devices.
Insider MonkeyAethlon Medical, Inc. (NASDAQ:AEMD) Q3 2024 Earnings Call Transcript
Aethlon Medical, Inc. (NASDAQ:AEMD) Q3 2024 Earnings Call Transcript February 14, 2024 Aethlon Medical, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and welcome to the Aethlon Medical Third Quarter Fiscal 2024 Earnings and Corporate Update. [Operator […]
PR NewswireAethlon Medical Announces Fiscal Third Quarter Financial Results and Provides Corporate Update
Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third quarter ended December 31, 2023 and provided an update on recent developments.
